EUVIMEDEUVIMED entdecken
Crossref

Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans

Taymeyah Al-Toubah, Jaime Montilla-Soler, Ghassan El-Haddad, Mintallah Haider, Jonathan Strosberg

Journal of Nuclear Medicine · 2023-12 · 64 (12) · 1895-1898

DOI: 10.2967/jnumed.123.266185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 05.10.2023. Verfasst von Taymeyah Al-Toubah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; and. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Organometallic Compounds. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatostatin receptor (SSTR) expression in metastatic lung neuroendocrine tumors (NETs) has not been well characterized using PET imaging. Understanding the degree and uniformity of SSTR expression is important to establish the role of SSTR-targeted treatments in lung NETs.

Methods

A retrospective institutional review of patients with metastatic lung NETs who underwent DOTATATE PET imaging from March 2017 to February 2023 was performed.

Results

In total, 48 patients with metastatic lung NETs who underwent 68Ga- or 64Cu-DOTATATE PET imaging were identified. Four had completely negative SSTR expression, and 10 had very weak expression (less than in a normal liver). Among the remaining 34 patients, 21 had uniformly positive DOTATATE PET scans, and 13 had heterogeneous expression. Only 44% had uniformly positive receptor expression, identifying them as candidates for peptide receptor radionuclide therapy.

Conclusion

Most metastatic lung NETs lack uniform SSTR expression and are thus suboptimal candidates for SSTR-targeted therapy. SSTR imaging in lung NETs should be evaluated carefully for uniformity of expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsCarcinoma, NeuroendocrineOrganometallic CompoundsHumansReceptors, SomatostatinRetrospective StudiesPositron-Emission TomographyLungPositron Emission Tomography Computed TomographyRadionuclide Imaging

Stichwörter der Autor:innen

64Cu-DOTATATE68Ga-DOTATATElung NETsneuroendocrine tumorssomatostatin expression

Substanzen

copper dotatate CU-64Receptors, SomatostatinOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; and.
  • Department of Diagnostic Imaging, Nuclear Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; and jonathan.strosberg@moffitt.org.

Zitieren

APA

Al-Toubah, T., Montilla-Soler, J., El-Haddad, G., Haider, M., & Strosberg, J. (2023). Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans. Journal of Nuclear Medicine, 64(12), 1895-1898. https://doi.org/10.2967/jnumed.123.266185

Vancouver

Al-Toubah T, Montilla-Soler J, El-Haddad G, Haider M, Strosberg J. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans. Journal of Nuclear Medicine. 2023;64(12):1895-1898. doi:10.2967/jnumed.123.266185

BibTeX
@article{AlToubah2023,
  author = {Al-Toubah, Taymeyah and Montilla-Soler, Jaime and El-Haddad, Ghassan and Haider, Mintallah and Strosberg, Jonathan},
  title = {Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {12},
  pages = {1895--1898},
  doi = {10.2967/jnumed.123.266185}
}
Kostenlos starten →